论文部分内容阅读
目的探讨新活素治疗急性失代偿性心力衰竭(ADHF)患者的临床疗效及安全性。方法将我院2012年3月-2013年3月122例ADHF患者随机分为两组各61例,对照组给予常规治疗,观察组在此基础上给予重组人脑利钠肽(新活素)进行治疗,7d后对两组数据进行统计分析。结果治疗前两组患者LVEF无统计学差异(P>0.05);治疗后,观察组患者LVEF值明显高于对照组(P<0.05),观察组总有效率高于对照组(P<0.05)。结论新活素可显著提高ADHF患者的左室射血分数,改善患者心功能,提高临床疗效,且安全性高,值得临床推广应用。
Objective To investigate the clinical efficacy and safety of nesiritin in the treatment of patients with acute decompensated heart failure (ADHF). Methods A total of 122 ADHF patients from March 2012 to March 2013 in our hospital were randomly divided into two groups of 61 cases. The control group was given routine treatment. The observation group was given recombinant human brain natriuretic peptide After treatment, the data of two groups were statistically analyzed after 7 days. Results There was no significant difference in LVEF between the two groups before treatment (P> 0.05). After treatment, the LVEF in observation group was significantly higher than that in control group (P <0.05), and the total effective rate in observation group was higher than that in control group (P <0.05) . Conclusions The new activin can significantly increase the left ventricular ejection fraction in patients with ADHF, improve cardiac function, improve clinical efficacy, and high safety, it is worthy of clinical promotion and application.